Suppr超能文献

强效且特异的线粒体 Sirtuins Sirt3 和 Sirt5 的激活剂。

Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5.

机构信息

Department of Biochemistry, University of Bayreuth, 95440 Bayreuth, Germany.

Department of Drug Chemistry and Technologies, Sapienza University of Rome, and Pasteur Institute, Cenci-Bolognetti Foundation, 00185 Rome, Italy.

出版信息

J Med Chem. 2022 Oct 27;65(20):14015-14031. doi: 10.1021/acs.jmedchem.2c01215. Epub 2022 Oct 13.

Abstract

Sirtuins are NAD-dependent protein deacylases involved in metabolic regulation and aging-related diseases. Specific activators for seven human Sirtuin isoforms would be important chemical tools and potential therapeutic drugs. Activators have been described for Sirt1 and act via a unique N-terminal domain of this isoform. For most other Sirtuin isoforms, including mitochondrial Sirt3-5, no potent and specific activators have yet been identified. We here describe the identification and characterization of 1,4-dihydropyridine-based compounds that either act as pan Sirtuin activators or specifically stimulate Sirt3 or Sirt5. The activators bind to the Sirtuin catalytic cores independent of NAD and acylated peptides and stimulate turnover of peptide and protein substrates. The compounds also activate Sirt3 or Sirt5 in cellular systems regulating, e.g., apoptosis and electron transport chain. Our results provide a scaffold for potent Sirtuin activation and derivatives specific for Sirt3 and Sirt5 as an excellent basis for further drug development.

摘要

Sirtuins 是依赖 NAD 的蛋白去酰基酶,参与代谢调节和与衰老相关的疾病。七种人类 Sirtuin 同工型的特异性激活剂将是重要的化学工具和有潜力的治疗药物。Sirt1 的激活剂已被描述,并通过该同工型的独特 N 端结构域发挥作用。对于大多数其他 Sirtuin 同工型,包括线粒体 Sirt3-5,尚未鉴定出有效的特异性激活剂。我们在这里描述了基于 1,4-二氢吡啶的化合物的鉴定和表征,这些化合物要么作为泛 Sirtuin 激活剂,要么特异性地刺激 Sirt3 或 Sirt5。这些激活剂与 Sirtuin 催化核心结合,不依赖 NAD 和酰化肽,并刺激肽和蛋白底物的周转。这些化合物还在调节细胞凋亡和电子传递链等的细胞系统中激活 Sirt3 或 Sirt5。我们的结果为有效的 Sirtuin 激活提供了一个支架,以及针对 Sirt3 和 Sirt5 的衍生物,这为进一步的药物开发提供了极好的基础。

相似文献

1
Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5.
J Med Chem. 2022 Oct 27;65(20):14015-14031. doi: 10.1021/acs.jmedchem.2c01215. Epub 2022 Oct 13.
2
Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5.
J Mol Biol. 2008 Oct 10;382(3):790-801. doi: 10.1016/j.jmb.2008.07.048. Epub 2008 Jul 25.
4
Using mitochondrial sirtuins as drug targets: disease implications and available compounds.
Cell Mol Life Sci. 2016 Aug;73(15):2871-96. doi: 10.1007/s00018-016-2180-7. Epub 2016 Mar 23.
8
Function and regulation of the mitochondrial sirtuin isoform Sirt5 in Mammalia.
Biochim Biophys Acta. 2010 Aug;1804(8):1658-65. doi: 10.1016/j.bbapap.2009.09.011. Epub 2009 Sep 18.
9
A molecular mechanism for direct sirtuin activation by resveratrol.
PLoS One. 2012;7(11):e49761. doi: 10.1371/journal.pone.0049761. Epub 2012 Nov 21.
10
Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition.
PLoS One. 2012;7(9):e45098. doi: 10.1371/journal.pone.0045098. Epub 2012 Sep 19.

引用本文的文献

1
Cardioprotection Through Pharmacological Activation of Sirtuin 5 in a Murine Model of Acute Myocardial Infarction.
Drug Des Devel Ther. 2025 Jun 27;19:5489-5505. doi: 10.2147/DDDT.S509337. eCollection 2025.
2
Unraveling Small Molecule-Mediated Sirtuin 3 Activation at a Distinct Binding Site for Cardioprotective Therapies.
ACS Cent Sci. 2025 Apr 14;11(5):704-718. doi: 10.1021/acscentsci.5c00023. eCollection 2025 May 28.
3
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
4
Biochemical characterization and discovery of inhibitors for Sir2A: new tricks for an old enzyme.
RSC Chem Biol. 2025 Jan 23;6(3):438-448. doi: 10.1039/d4cb00206g. eCollection 2025 Mar 5.
5
Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.
Theranostics. 2024 Oct 14;14(17):6726-6767. doi: 10.7150/thno.100667. eCollection 2024.
6
Activation and inhibition of sirtuins: From bench to bedside.
Med Res Rev. 2025 Mar;45(2):484-560. doi: 10.1002/med.22076. Epub 2024 Aug 31.
8
Pharmacological Activation of SIRT3 Modulates the Response of Cancer Cells to Acidic pH.
Pharmaceuticals (Basel). 2024 Jun 20;17(6):810. doi: 10.3390/ph17060810.
10
Mitochondrial Sirtuins in Cancer: A Revisited Review from Molecular Mechanisms to Therapeutic Strategies.
Theranostics. 2024 May 11;14(7):2993-3013. doi: 10.7150/thno.97320. eCollection 2024.

本文引用的文献

1
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Gastroenterology. 2021 Nov;161(5):1584-1600. doi: 10.1053/j.gastro.2021.06.045. Epub 2021 Jul 8.
2
Binding site for activator MDL-801 on SIRT6.
Nat Chem Biol. 2021 May;17(5):519-521. doi: 10.1038/s41589-021-00749-y. Epub 2021 Mar 1.
3
SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury.
Aging (Albany NY). 2020 Jul 28;12(16):16224-16237. doi: 10.18632/aging.103644.
4
Structural basis for the activation and inhibition of Sirtuin 6 by quercetin and its derivatives.
Sci Rep. 2019 Dec 16;9(1):19176. doi: 10.1038/s41598-019-55654-1.
5
Mechanism of activation for the sirtuin 6 protein deacylase.
J Biol Chem. 2020 Jan 31;295(5):1385-1399. doi: 10.1074/jbc.RA119.011285. Epub 2019 Dec 10.
7
Identification of a cellularly active SIRT6 allosteric activator.
Nat Chem Biol. 2018 Dec;14(12):1118-1126. doi: 10.1038/s41589-018-0150-0. Epub 2018 Oct 29.
8
CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer.
Cancer Sci. 2018 Aug;109(8):2590-2598. doi: 10.1111/cas.13691. Epub 2018 Jul 10.
10
Sirtuin activators and inhibitors: Promises, achievements, and challenges.
Pharmacol Ther. 2018 Aug;188:140-154. doi: 10.1016/j.pharmthera.2018.03.004. Epub 2018 Mar 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验